Peptide Synthesis Market

The Peptide Synthesis Market is valued at USD 1.1 Bn in 2026 and is projected to reach USD 1.5 Bn, growing at a CAGR of 5% by 2033.

Peptide synthesis has become one of the most important methodologies in bioorganic chemistry. Advancements in chemistry and technology have led to vastly improved synthesis methods. Peptides have proven to be critical elements of biomedical research, and peptide synthesis continues to fuel scientific progress worldwide. Synthetic peptides serve as probes of biological structure and function and act as important intermediates for the development of enzyme inhibitors and peptidomimetics as therapeutic agents. The therapeutic potential of peptides has drawn the attention of various pharmaceutical companies, and several drugs made from peptides have received FDA approval and reached the market. This is likely to predominantly drive the growth of peptide synthesis market. The efficacy, specificity, and low toxicity of peptides assures us that peptides will continue to be pursued and developed for pharmaceutical and diagnostic purposes and will remain a growing area of biochemical research. Peptide synthesis market is thus expected to be on an uptrend.

The rising usage of peptides in pharmaceutical treatments, an increase in research activities and the availability of funds for R&D, and the development of improved automated peptide synthesisers are driving the growth of peptide synthesis market. Peptide molecules have gained enormous traction in the healthcare and nutrition industries, and various technological improvements have been made to achieve desired peptide production/synthesis. This pattern has been found in both enzymatic and chemical peptide production. The increase in research expenses will give more potential prospects for expanding the peptide synthesis market in the coming years.

High Number of FDA-approved Drugs, and Several in the Pipeline Warrant Sustained Peptide Consumption

Peptides are pharmacological compounds that are both highly active and very selective. They are used in various therapeutic areas due to the diversity of their biological actions. With their broad chemical space, high physical activity, high specificity, the relative simplicity of synthesis, accessible availability, and low toxicity, peptides rapidly enter drug development paths as active medicinal components. There are already over 100 FDA-approved peptide-based medications on the market. With over 700 peptide medicines and therapeutic peptides currently in clinical trials or preclinical development, this figure is projected to expand dramatically.

Peptides are also in high demand for treating cardiovascular and neurological illnesses, renal failure, and uncommon diseases. Peptides generate billions of dollars in revenue across three primary therapeutic areas: cancer, diabetes, and obesity. According to WHO, CVDs kill 17.9 million people yearly, accounting for an estimated 32% of all deaths worldwide, with more than 75% of CVD-related deaths occurring in low- and middle-income countries. The growing prevalence of cardiovascular disease will increase the demand for peptides in the coming years, in turn pushing the prospects of peptide synthesis market.

Reagents Continue to Dominate Peptide Synthesis Market with their Phenomenal Binding Properties

The reagents segment will control most of the peptide synthesis market. The growing applications of peptides in therapeutics, drug design, and gene synthesis; the frequent purchase of reagents as opposed to equipment; the increasing number of ongoing research projects involving peptide synthesis; and the market availability of various peptide synthesis reagents can all be attributed to the large share of this segment. High research and development expenses by biotechnology companies, an increase in the number of biotechnology firms, an increase in biopharmaceuticals, and technological advancements are projected to drive the growth of the reagents segment during the forecast period. The rising use of biotechnology reagents in medicines, commercial applications, and fundamental research are just a few of the factors expected to drive the growth of the reagents sector.

The US Leads with Greater Emphasis on Personalised Therapeutics, and Effort Toward Commercialisation of Peptide Therapeutics

North America contributed the most to the worldwide market, owing to the strong presence of significant market participants, improved awareness about accessible peptide synthesis methods, and a growing emphasis on commercialising peptide therapeutics. Increased life science R&D, a high prevalence of chronic diseases, increased investments in the development of structure-based drug designs, increased research in genomics and proteomics, and a greater emphasis on developing personalised therapeutics all contribute to North America's significant share in global peptide synthesis market. The US will hold the most significant proportion of the North American market in the forecast period. The substantial share of the US is primarily due to increased life science research activities in the US and the increasing prevalence of cancers, and other chronic disorders. Diabetes affects an estimated 34.2 million individuals (10.5 percent of the U.S. population), and they are projected to continue, resulting in increased demand for peptide therapies, which will drive the market in the area.

Asia Pacific is expected to exhibit the fastest growth during the forecast period due to increased investments by market players in the region, growing awareness about novel peptide treatments, increased healthcare spending by governments as well as patients, distribution collaborations undertaken by multinational companies with local players, and rising incidence of chronic diseases in low- and middle-income countries. According to WHO, approximately 8.5 million people die yearly in Southeast Asia due to chronic diseases. The increased awareness of novel peptide therapeutics and rising healthcare expenditure is expected to drive the growth of the peptide synthesis market in the area in the coming years.

Participants in the market are introducing new products and forming collaborations, alliances, and partnership agreements. In April 2020, GenScript announced a Neoantigen Specific Peptide Synthesis Service to develop precision immuno-oncology therapeutics. In contrast to established targets such as tumor-associated antigens, neoantigens are new peptides found only in tumor cells and not in healthy tissue. In April 2020, JPT Peptide Technologies released ready-to-use peptide tools for investigating and profiling the immune response to SARS-CoV-2 infection. Peptide Microarrays with high content covering all proteins of SARS-CoV-2 and structural antigens of SARS-CoV, MERS-CoV, and common cold coronaviruses, PepMixTM Peptide Pools with several SARS-CoV-2 antigens, Epitope Mapping Sets, and individual Epitope Peptides are among the key offerings.

A few of the players in the peptide synthesis market include:

• AAPPTec
• Biotage AB
• BASF
• Bachem Holding AG
• CSBio Company Inc.
• CEM Corporation
• GfN
• Geltor

Global Peptide Synthesis Market is Segmented as below:

By Product & Service

• Reagents
• Equipment
• Services

By Reagents

• Resins
• Amino acids
• Coupling Reagents
• Dyes and Fluorescent labeling reagents
• Other Reagents

By Equipment

• Peptide Synthesizers
• Chromatography Equipment
• Lyophiizers

By Technology

• Solid-Phase Peptide Synthesis
• Solution-Phase Peptide Synthesis
• Hybrid & Recombinant Technology

By End-user

• Pharmaceutical & Biotechnology companies
• CDMOs & CROs
• Academic & Research Institutes

By Region

• North America
• Europe
• Asia Pacific
• LAMEA